MilliporeSigma

Viral Vector Upstream Platforms

Gene therapies use viral vectors to introduce modified genetic material into cells. Manufacturing starts with the upstream production of viral vectors which are then purified and concentrated during downstream processing.  

The main challenges in upstream processing include productivity, product quality, process robustness, and scalability for commercial manufacturing. Our optimized upstream platforms minimize these challenges and are supported by technical and regulatory experts to help you make the right decisions at every step and stage of your process. 

Learn how to speed your viral vector-based cell and gene therapy development.


Products
Loading

Our upstream platforms pair a cell line and cell culture medium, optimized for productivity. Although optimized to work together, each cell line and cell culture medium can be used independently. The platforms are supported with detailed protocols developed by our technical experts to achieve optimal performance, saving you time in process development and speeding delivery of your therapy to patients.

Key benefits of our cell lines:

  • GMP-banked, fully characterized and tested for adventitious agents
  • Licenses available for research or clinical/commercial use
  • Fully traceable and with documentation for regulatory filings

Key benefits of our cell culture media :

  • Chemically defined, animal component-free
  • GMP compliant manufacturing
  • Available in liquid and dry powder formats

Upstream Cell Lines and Cell Culture Media


THE VIRUSEXPRESS® LENTIVIRAL PLATFORM

For Saving Time in Process Development of Lentiviral Vector-Based Cell Therapies.

The VirusExpress® Lentiviral Platform is a transfection-based solution to lentiviral production challenges and offers a scalable upstream process optimized for suspension-based lentivirus production.

Key benefits of HEK293T VirusExpress® Cells

  • Cell line grows to high cell density and viability in suspension and has low doubling time
  • Selected for higher lentivirus production using PEI-based transient transfection method
  • GMP-banked, fully characterized and adventitious agent tested
  • Licenses available for research or clinical/commercial use.
  • Fully traceable and documentation available for regulatory filings

Key benefits of EX-CELL® CD HEK293 Viral Vector Medium

  • Supports high cell density and faster growth of HEK293T cells
  • Compatible with the PEI based transfection reagents used for viral production
  • Eliminates need for transfection step boost and enhancer reagents
  • Chemically defined, animal component-free
  • GMP compliant manufacturing
  • Available in liquid and dry powder formats

VirusExpress® Lentiviral Platform Performance


THE VIRUSEXPRESS® AAV PLATFORM

For Saving Time in Process Development of HEK293 Cells Based  Gene Therapies.

The VirusExpress® AAV Platform offers a transfection-based solution to AAV production challenges, and an upstream process optimized for scalable, suspension-based AAV production.

Key benefits of HEK293 VirusExpress® Cells

  • Cell line grows to high cell density and viability in suspension and has low doubling time
  • Selected for higher AAV production using PEI-based transient transfection method
  • GMP-banked, fully characterized and adventitious agent tested
  • Licenses available for research or clinical/commercial use
  • Fully traceable and documentation available for regulatory filings

Key benefits of Cellvento® 4HEK Medium

  • Maximizes viable cell density and AAV productivity
  • Supports growth of multiple HEK293 cell lines with diverse nutritional requirements
  • Compatible with the PEI based transfection reagents used for AAV production
  • Chemically defined, animal component-free cell culture medium
  • GMP compliant manufacturing
  • Available in liquid and dry powder formats

VirusExpress® AAV Production Platform Performance

 


THE Sf-RVN® PLATFORM

For Improving the Safety Profile of Your Insect Cell Based Gene Therapies.

Insect cell expression systems are an appealing alternative for AAV production as they are easy to cultivate and do not rely on transfection. However, as many Sf-9 insect cell lines are contaminated with Sf-Rhabdovirus, the Sf-Rhabdovirus negative Sf-9 cell line (Sf-RVN®) offers an improved viral safety profile and is an attractive option for scalable AAV production.

The Sf-RVN® Platform includes a Sf-Rhabdovirus-free cell line with enhanced risk mitigation, and provides a high-performance, scalable platform optimized for AAV production.

Key benefits of Sf-RVN® Insect Cell Line

  • A proven Sf-Rhabdovirus-negative Sf-9 cell line
  • Same characteristics as Sf-9 cells
  • GMP-banked, fully characterized and adventitious agent tested
  • Licenses available for research or clinical/commercial use
  • Fully traceable and documentation available for regulatory filings

Key benefits of EX-CELL® CD Insect Cell Medium

  • Optimized for growth and productivity of Sf-9 cells
  • Supports growth of multiple insect cell lines (Sf-21, S2, Tni and C636)
  • Chemically defined and animal component free
  • GMP compliant manufacturing
  • Available in liquid and dry powdered medium

Related Product Resources






Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?